ADVENTRX Pharmaceuticals (ANX) Reports In-Line Q3 EPS Loss of $0.13
Tweet
Share
E-mailGet Alerts ANX Hot Sheet
Join SI Premium – FREE
ADVENTRX Pharmaceuticals (NYSE: ANX) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
